睿知中国疾病研究地图
候选清单0

北京首都医科大学

首都医科大学附属北京佑安医院

Beijing Youan Hospital, Capital Medical University

在本站收录的 53 种疾病中,这家医院列在其中 7 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

首都医科大学附属北京佑安医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma67 篇牵头论文
  2. 骨肉瘤Osteosarcoma1 篇牵头论文
  3. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  4. 肝豆状核变性Wilson disease5 篇牵头论文
  5. 肝包虫病Hepatic echinococcosis0 篇牵头论文
  6. 原发性胆汁性胆管炎Primary biliary cholangitis6 篇牵头论文
  7. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 67 篇,占 0.4%。

牵头论文
67
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 151520222023: 111120232024: 161620242025: 12122025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07479485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、福州、郑州

  2. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  3. 正在招募
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    分期
    II期
    开始
    2025-12
    登记号
    NCT07324304

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、哈尔滨、杭州

  4. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后乙肝与肝硬化影像、人工智能与早期发现
论文中的科室消化/肝病科肿瘤内科普外/肝胆胰外科影像/核医学科
牵头的论文67
  1. Contrast-enhanced MRI for identifying the steatohepatitic hepatocellular carcinoma from small hepatocellular carcinoma.2026Abdominal radiology (New York)
  2. Machine Learning-Based Model for Predicting Recurrence-Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients.2025Cancer medicine免费全文
  3. Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. Emerging roles of cuproptosis in liver diseases.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  5. Integrating single-cell RNA sequencing with spatial transcriptomics reveal the fibrosis-related genes in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  6. A prediction model based on machine learning: prognosis of HBV-induced HCC male patients with smoking and drinking habits after local ablation treatment.2025Frontiers in immunology免费全文
  7. The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma.2025Frontiers in immunology免费全文
  8. The Roles and Clinical Significance of Major Hepatic-Derived Metabolites in Hepatocellular Carcinoma.2025Journal of gastroenterology and hepatology免费全文
  9. Oral Chinese patent medicine combined with transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A Bayesian network meta-analysis.2025Medicine免费全文
  10. Immune Escape-Related Gene NXT1 as a Potential Prognostic and Therapeutic Target in Hepatocellular Carcinoma.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  11. The methylation signature of hepatocellular carcinoma trajectory based on pseudotime and chronological time for predicting precancerous patients.2025The oncologist免费全文
  12. Predictive Value of Preoperative Serum Substance P Levels for Post-Transplant Recurrence in Patients With Hepatocellular Carcinoma.2025Transplantation proceedings
  13. A Novel Nomogram for Predicting Recurrence of Hepatocellular Carcinoma After Liver Transplantation.2025Transplantation proceedings
  14. Reduced muscle mass is an important part of Global Leadership Initiative on Malnutrition criteria in nutritional diagnosis of hepatocellular carcinoma.2024BMC gastroenterology免费全文
  15. Immunotherapy for hepatocellular carcinoma.2024Chinese medical journal免费全文
  16. A Systematic Review and Meta-Analysis of MRI Radiomics for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma.2024Current medical imaging
  17. Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study.2024European journal of radiology
  18. Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study.2024Frontiers in immunology免费全文
  19. Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score.2024Frontiers in immunology免费全文
  20. Nomogram for predicting post-therapy recurrence in BCLC A/B hepatocellular carcinoma with Child-Pugh B cirrhosis.2024Frontiers in immunology免费全文
  21. Construction and validation of a machine learning-based nomogram to predict the prognosis of HBV associated hepatocellular carcinoma patients with high levels of hepatitis B surface antigen in primary local treatment: a multicenter study.2024Frontiers in immunology免费全文
  22. Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma.2024Frontiers in immunology免费全文
  23. Hu-Qi-Zheng-Xiao Decoction Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Suppressing the HIF-1α Signaling Pathway to Inhibit EMT, LCSC, and Angiogenic Process.2024Integrative cancer therapies免费全文
  24. HBx-induced upregulation of MAP1S drives hepatocellular carcinoma proliferation and migration via MAP1S/Smad/TGF-β1 loop.2024International journal of biological macromolecules
  25. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.2024Journal of cancer research and clinical oncology免费全文
  26. Diagnostic value of serum STIP1 in HCC and AFP-negative HCC.2024Laboratory medicine免费全文
  27. Relationship between STAP1 methylation in peripheral blood T cells and the clinicopathological characteristics and prognosis of patients within 5-cm diameter HCC.2024Minerva gastroenterology
  28. Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma.2024Scandinavian journal of gastroenterologyRCT
  29. Unraveling the Heterogeneity of Tumor Immune Microenvironment in Hepatocellular Carcinoma by SingleCell RNA Sequencing and its Implications for Prognosis and Therapeutic Response.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  30. Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence.2023BMC cancer免费全文
  31. Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network.2023Chinese medical journalRCT免费全文
  32. CT radiomics for prediction of microvascular invasion in hepatocellular carcinoma: A systematic review and meta-analysis.2023Clinics (Sao Paulo, Brazil)免费全文
  33. Reprogramming of lipid metabolism in hepatocellular carcinoma resulting in downregulation of phosphatidylcholines used as potential markers for diagnosis and prediction.2023Expert review of molecular diagnostics
  34. Impact of Traditional Chinese Medicine on Prognosis of Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.2023Integrative cancer therapies免费全文
  35. Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis.2023Journal of cancer research and clinical oncology免费全文
  36. CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.2023Journal of viral hepatitis
  37. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.2023Journal of viral hepatitis
  38. The Advancement of Nanomaterials for the Detection of Hepatitis B Virus and Hepatitis C Virus.2023Molecules (Basel, Switzerland)免费全文
  39. mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid.2023Naunyn-Schmiedeberg's archives of pharmacology
  40. Dynamic Changes of Cytokine Profiles and Their Correlation With Tumor Recurrence Following Thermal Ablation in Hepatocellular Carcinoma.2023Technology in cancer research & treatment免费全文
  41. The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy.2022BMC gastroenterology免费全文
  42. ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study.2022Biochemical and biophysical research communications
  43. Knockout of ASPP2 promotes DEN-induced hepatocarcinogenesis via the NF-κB pathway in mice.2022Cancer gene therapy免费全文
  44. Inactivation of tumor suppressor TAp63 by hepatitis B virus X protein in hepatocellular carcinoma.2022Chinese medical journal免费全文
  45. Digital Droplet PCR for Detection and Quantitation of Hepatitis Delta Virus.2022Clinical and translational gastroenterology免费全文
  46. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.2022Clinical transplantation
  47. Epidemic, risk factors of carbapenem-resistant Klebsiella pneumoniae infection and its effect on the early prognosis of liver transplantation.2022Frontiers in cellular and infection microbiology免费全文
  48. Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy.2022Frontiers in immunology免费全文
  49. Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation.2022Frontiers in immunology免费全文
  50. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma.2022Frontiers in immunology免费全文
  51. m7G regulator-mediated methylation modification patterns define immune cell infiltration and patient survival.2022Frontiers in immunology免费全文
  52. Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.2022Frontiers in immunology免费全文
  53. Comprehensive Analysis of Epigenetic Associated Genes on Differential Gene Expression and Prognosis in Hepatocellular Carcinoma.2022Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  54. AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R.2022Molecules (Basel, Switzerland)免费全文
  55. Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China.2022PeerJ免费全文
  56. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.2021BMC cancer免费全文
  57. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.2021BMC gastroenterology免费全文
  58. Interferon-Induced Transmembrane Protein 3 Expression Upregulation Is Involved in Progression of Hepatocellular Carcinoma.2021BioMed research international免费全文
  59. Crosstalk between hepatic stellate cells and tumor cells in the development of hepatocellular carcinoma.2021Chinese medical journal免费全文
  60. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  61. Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials.2021Journal of gastroenterology and hepatology
  62. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response.2021Journal of immunology research免费全文
  63. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.2021Journal of viral hepatitis免费全文
  64. Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.2021Medicine免费全文
  65. Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.2021Medicine免费全文
  66. Intracellular alpha-fetoprotein interferes with all-trans retinoic acid induced ATG7 expression and autophagy in hepatocellular carcinoma cells.2021Scientific reports免费全文
  67. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.2021The oncologist免费全文
中文论文(未计入)10
  1. [Research advances in occurrence risk assessment and early-stage diagnosis of hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Factors affecting tumorigenicity in liver cancer xenografts].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Advances in serological non-invasive diagnosis for metabolic dysfunction-associated fatty liver disease].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Exploration of cystathionine β-synthase and cystathionine γ-lyase gene expression poor prognostic predictive value with the application of bioinformatics data mining in liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  6. [The study of a key molecule Caspase-1 of inflammasome in hepatitis B virus-related diseases].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  7. [Recommendations of EASL clinical practice guidelines on haemochromatosis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  8. [Research progress in radiomics based on CT and MRI images for prediction of microvascular invasion in hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  9. [Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  10. [Study of the risk factors for recurrence of early and late stage hepatocellular carcinoma after hepatic artery embolization combined with radiofrequency ablation therapy].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy状态不明NCT05962450牵头方II期2023-10 启动
  2. Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC已完成NCT04011033牵头方II期2018-03 启动
  3. Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC状态不明NCT03175705牵头方I期2017-05 启动
  4. Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC已完成NCT03175679牵头方I期2017-04 启动
  5. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)正在招募NCT07479485研究中心I/II期2026-04 启动
  6. NWRD06 DNA Plasmid for HCC After Curative Resection.正在招募NCT07324304研究中心II期2025-12 启动
  7. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  8. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  9. A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma进行中,不再招募NCT07713290研究中心I期2025-04 启动
  10. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  11. Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma已完成NCT07845266研究中心I期2024-04 启动
  12. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  13. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients状态不明NCT05343832研究中心2021-11 启动
  14. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  15. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)已完成NCT04000737研究中心II期2020-01 启动
  16. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  17. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  18. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动
  19. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题EB病毒与感染诱因诊断与预后

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.5%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

北京有 3 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
    分期
    III期
    开始
    2026-09
    登记号
    NCT07465718

    年龄 8 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州

  2. 正在招募
    China Registry for Genetic / Metabolic Liver Diseases
    分期
    未注明
    开始
    2015-06
    登记号
    NCT03131427

    年龄未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传学(ATP7B)诊断与铜代谢检测治疗(螯合剂、锌剂)
论文中的科室消化/肝病科
牵头的论文5
  1. Emerging roles of cuproptosis in liver diseases.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  2. Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets.2025Journal of cellular and molecular medicine免费全文
  3. The potential serum sphingolipid biomarkers for distinguishing Wilson disease.2024Clinica chimica acta; international journal of clinical chemistry
  4. Wilson disease in pregnancy: A case series.2023Medicine免费全文
  5. Stem Cells Treatment for Wilson Disease.2022Current stem cell research & therapy
中文论文(未计入)9
  1. [Recommendations from the European Association for the Study of the Liver and the European Reference Network for Rare Liver Diseases Clinical Practice Guidelines for hepatolenticular degeneration].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Progress on the research of hepatolenticular degeneration].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Inherited metabolic liver disease causing copper deposition].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Research progress of inherited metabolic liver disease in 2024].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [Application of zinc agents in Wilson's disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  6. [An introduction to multidisciplinary recommendations for Wilson's disease comprehensive diagnosis and management: 2022 practice guidance from the American Association for the Study of Liver Diseases].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  7. [Interpretation of the 2022 edition guidelines for hepatolenticular degeneration diagnosis and treatment].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  8. [Management of hepatolenticular degeneration during pregnancy].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  9. [Research progress in gene therapy for Wilson's disease].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.正在招募NCT07465718研究中心III期2026-09 启动
  2. China Registry for Genetic / Metabolic Liver Diseases正在招募NCT03131427研究中心2015-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 6 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.0%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 222025

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文6
  1. Non-invasive assessment of esophageal and fundic varices in patients with primary biliary cholangitis.2025European radiology
  2. Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia.2025Frontiers in immunology
  3. A new method to estimate the histological stage of primary biliary cholangitis.2024European radiology
  4. Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients.2023Frontiers in endocrinology
  5. Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: A real-world retrospective study of 537 patients in China.2022Frontiers in immunology
  6. Disease predisposition of human leukocyte antigen class II genes influences the gut microbiota composition in patients with primary biliary cholangitis.2022Frontiers in immunology
中文论文(未计入)1
  1. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
早期论文(2016–2020 年)5
  1. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.2019Disease markers
  2. [An analysis of the serological characteristics of anti-mitochondrial M2 subtype in patients with drug-induced liver injury and primary biliary cholangitis].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis.2018Liver international : official journal of the International Association for the Study of the Liver
  4. [How to understand the clinical significance of autoantibodies in primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  5. Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis.2016Journal of immunology (Baltimore, Md. : 1950)
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  4. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis进行中,不再招募NCT05050136研究中心II期2021-09 启动
  5. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
中文论文(未计入)1
  1. [Gastrointestinal endoscopy in the diagnosis and treatment of biliary liver disease].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. PSC Clinical Epidemiology in China状态不明NCT04981756研究中心2021-04 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京佑安医院

Beijing Youan Hospital, Capital Medical University

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Beijing Youan Hospital; Beijing You An Hospital; Capital Medical University affiliated Beijing You An Hospital; Beijing You An Hospital Affiliated to the Capital Medical University; Capital Medical University Affiliated Beijing Youan Hospital; Beijing YouAn Hospital Capital Medical University; Beijing Youan Hospital Affiliated with Capital Medical University; Beijing Youan Hospital of Capital Medical University

提出更正下载数据